Generic Ketamine vs Spravato (Esketamine): Online Treatment Options Compared

Generic ketamine vs Spravato online treatment options compared: Spravato is not an online treatment option because it must be administered at a certified healthcare setting under its FDA-required REMS program. What patients often call generic ketamine is usually compounded racemic ketamine prescribed off-label and used at home through some telehealth programs. The practical choice often comes down to diagnosis, insurance coverage, access to in-person care, cost, and the level of monitoring a patient and clinician consider appropriate.

Neither option is automatically the better fit for every person. A qualified prescriber should assess diagnosis, treatment history, medical history, medications, safety considerations, and local prescribing requirements.

What each treatment is

Compounded ketamine is a pharmacy-prepared medication that may contain racemic ketamine, a mixture of the R and S forms of ketamine. It is commonly dispensed as sublingual tablets, troches, or lozenges by telehealth ketamine providers. Although ketamine has long been FDA-approved as an anesthetic, compounded ketamine is not FDA-approved for depression, anxiety, PTSD, or other psychiatric uses.

The FDA has warned that compounded ketamine products are not evaluated for safety, effectiveness, or quality in the same way as FDA-approved drugs, and that at-home use requires careful clinical oversight. See the FDA's advisory on compounded ketamine products for its current safety information.

Spravato is the brand name for esketamine, which contains the S form of ketamine and is delivered as a nasal spray. The FDA approved Spravato in 2019 for adults with treatment-resistant depression and later approved it for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. The FDA's Spravato approval announcement describes the treatment and its safety requirements.

Administration and access

At-home compounded ketamine is designed around remote access. After a clinical evaluation, a participating prescriber may send a prescription to a compounding pharmacy, which ships medication to the patient where permitted. Session instructions, follow-up cadence, support availability, and safety screening differ between providers. Read the telehealth ketamine legality overview and the guide to interstate prescribing to understand why availability can differ by state.

Spravato follows a different model. Under the Spravato REMS, certified pharmacies dispense it only to certified healthcare settings, where patients self-administer the nasal spray under observation. Patients are monitored for at least two hours after dosing, and should not drive or operate machinery until the next day after a restful sleep. The manufacturer describes these requirements in the Spravato REMS program.

This distinction matters for access. Telehealth may reduce travel for an eligible patient seeking compounded ketamine, while Spravato requires travel to a participating facility for every session. On the other hand, in-person monitoring may appeal to patients who prefer supervised administration or whose clinician believes that setting is more appropriate.

Cost and insurance expectations

Costs vary by provider, dose, follow-up structure, pharmacy, location, and insurance benefits. The supplied program pricing for telehealth compounded ketamine is typically $129-$400 per month, often covering medication and varying levels of consultation or support. Patients should confirm exactly what a quoted monthly fee includes.

Spravato's historical wholesale acquisition cost has been reported at roughly $590-$885 per treatment session depending on dose, before facility, professional, and monitoring charges. An Institute for Clinical and Economic Review report reported those list-price figures. Actual patient costs can differ substantially because insurers, facilities, and assistance programs use different arrangements.

Insurance can change the comparison. Spravato may be covered by commercial plans, Medicare, or some Medicaid programs when plan criteria are met, often with prior authorization and documented treatment history. Compounded ketamine used off-label is commonly not covered. For payment questions, see Does Medicare cover ketamine therapy? and compare monthly subscription and per-session care models.

How the clinical evidence differs

Spravato's labeled uses were evaluated through the FDA review process and clinical trials submitted for approval. That does not mean every person responds, but it provides an evidence base for the specific indications in its prescribing information.

Racemic ketamine has been studied for depression across several administration routes for decades. Evidence for at-home sublingual compounded ketamine is growing, but much of it is observational and does not match the large randomized trials used to support Spravato's approval. Researchers continue to study whether the two forms differ in effect, durability, and tolerability. Patients should be cautious about direct dose comparisons because delivery route, absorption, formulation, and monitoring setting are not interchangeable. See why ketamine and esketamine dose equivalence is not straightforward.

Which option may fit which patient?

Spravato may be worth discussing with a clinician for an adult with treatment-resistant depression who can attend regular in-person sessions and wants to explore insurance coverage for an FDA-approved treatment. It may be less practical for someone unable to travel to a certified site or unable to arrange the time required after each session.

At-home compounded ketamine may be a discussion point for someone whose clinician believes off-label treatment is appropriate and who has access to a provider offering adequate screening, instructions, and follow-up. It is not a substitute for individualized assessment, and it may not be suitable for people whose history or current symptoms call for a higher level of care. People with persistent depression can also review next steps for treatment-resistant depression before choosing a treatment path.